I'll research DuPont (DD) before writing the preview. Let me start by gathering recent filings, earnings materials, and news.Let me read the most recent earnings materials and the investor day, and check for recent news.Let me pull recent stock price performance and check for any late-breaking news.Let me quickly pull the medium-term targets from the September 2025 Investor Day to round out the picture.# DuPont (DD) — Q2 2026 Earnings Preview
This is only the second full quarter of the "New DuPont" — a much smaller, more focused portfolio following two major structural moves:
DuPont now reports in two segments: Healthcare & Water Technologies (~half of sales, higher growth/margin) and Diversified Industrials (~half, building + industrial). Both electronics and aramids are treated as discontinued operations, so all comparisons this quarter are on a continuing-ops, "pro-forma" basis. Investors should keep the pro-forma framing front-and-center — reported growth rates carry a ~2-3% currency element on top of organic.
Momentum going in is good: Q1 2026 beat guidance, with organic sales +2%, ~130 bps of pro-forma margin expansion, double-digit adjusted EPS growth, and management raised full-year guidance.
Management's own Q2 guidance (set on the May call) is the bar:
| Metric | Q2'26 Guide | Q1'26 Actual | Notes |
|---|---|---|---|
| Net sales | ~$1.80B | $1.68B | Guide assumes ~3% organic, slight FX tailwind |
| Operating EBITDA | ~$430M | $414M | Implies margin stepping down to ~24% from 24.6% |
| Adjusted EPS | ~$0.59 | $0.55 | vs. $0.55 in Q1 |
Full-year 2026 guidance (raised in May): Net sales $7.155–$7.215B (~4% organic, incl. ~1% price), Operating EBITDA $1.73–$1.76B, Adjusted EPS $2.35–$2.40 (24–25% tax rate).
A key structural note management flagged: first-half sales and EBITDA should each represent ~48% of full-year results at the midpoint, in line with historical seasonality — so a clean first half sets up a normally back-half-weighted year.
1. Do they raise full-year guidance again? DuPont raised the FY guide in May on the Q1 beat plus Aramids interest income. Given a strong Q1 and constructive April/order commentary, the debate is whether a Q2 beat drives another hike — or whether management stays conservative given macro/geopolitical uncertainty. Watch the tax rate (now guided 24-25%) and interest income as additional EPS levers.
2. The margin step-down — is it just optics? Q1 margin of 24.6% was unusually strong (mix added ~50 bps, net productivity ~70 bps). Management explicitly guided Q2 down ~40 bps on mix and ~30 bps on price-cost timing, so a print near ~24% is expected, not a red flag. The real question is whether underlying productivity keeps DuPont ahead of its 150–200 bps of margin expansion by 2028 target (25%+ EBITDA margin). Management said in May it was "well on its way."
3. Middle East / Water — the swing factor. The Middle East conflict is the biggest external variable. Total DuPont exposure to the region is ~$300M (~4% of sales), split roughly evenly between sales into and inputs sourced from the region. In Q1, ~$10M of Water sales couldn't ship (those shipped in April). Management said the teams found alternative routes and did not bake heavy Q2 disruption into guidance. Watch: (a) any escalation, (b) whether the large second-half Middle East desalination projects remain on track, and (c) the full-year Water setup — roughly flat 1H, up high-single-digits 2H, landing at mid-single-digits, driven by project timing.
4. Price-cost execution. DuPont expects ~$90M of incremental input costs (HDPE for Tyvek, styrene for Water/Shelter) from the conflict, which it intends to fully offset with ~1% of pricing/surcharges. Most increases took effect May 1, so Q2 is the first quarter with real price flowing (~$25M on the top line), and the second half carries the full run-rate. Watch for customer pushback and whether price fully covers cost as guided.
5. Segment demand trends: - Healthcare (strong): Q1 organic up high-single-digits on medical packaging (Tyvek), biopharma (Liveo) and med device (Spectrum/Donatelle). Guided to mid-to-high-single-digits for the year. This is the growth engine — watch for continued biopharma recovery and any M&A hints. - Water: Underlying consumables (~70% recurring/replacement revenue) growing nicely; microelectronics (ion exchange for semis/AI data centers) a new callout. - Building Technologies (weak): Construction still soft (esp. N.A. resi); management assumes roughly flat construction for the year with a modest 1H-down/2H-up shape. No recovery is baked in — an optionality lever if rates help. - Industrial Technologies (strong): Aerospace (Vespel) and automotive, driven by EV battery adhesives (~$300M EV sales, growing well above the ~20% EV market rate as new wins ramp). Watch printing/packaging (inks), which was a Q1 drag on tough comps.
DD has re-rated meaningfully since the Qnity spin: from ~$104 in early November 2025 to a high of ~$154 in mid-February 2026, before pulling back. Shares closed around $141 on Aug 3, roughly +15% YTD but ~8-9% below the February high. The Q1 beat was rewarded with an ~8% single-day pop (May 5).
On the FY26 adjusted-EPS midpoint (~$2.37), the stock trades at a rich forward multiple (~50-60x P/E; note this is continuing-ops adjusted EPS with heavy intangible amortization of ~$0.51/share, and EV/EBITDA in the mid-30s) — a premium that appears to embed the higher-growth healthcare/water mix, self-help margin story, and M&A/capital-return optionality. This leaves little room for disappointment: a clean beat-and-raise is arguably needed to hold the multiple, while any Middle East escalation, Water project slippage, or PFAS surprise could pressure the shares.
Given a premium valuation and a strong Q1 setting a high bar, this is a report where execution consistency and a confident tone on guidance matter as much as the headline beat.
Note: Full-year and Q2 figures reflect management's own guidance; formal sell-side consensus was not available in the sources reviewed. All comparisons are on a continuing-operations, pro-forma basis unless stated otherwise.